Upper Limb Treatment With "Gloreha Aria" in the Hemiplegic Patients

Sponsor
Istituti Clinici Scientifici Maugeri SpA (Other)
Overall Status
Completed
CT.gov ID
NCT03738813
Collaborator
(none)
30
1
2
38.2
0.8

Study Details

Study Description

Brief Summary

Stroke is one of the leading causes of death and disability and has been described as a worldwide epidemic (1). Stroke survivors are affected by impairments and limitations of cognitive, language, perceptual, sensory, and motor functions. After a stroke, patients can improve spontaneously within the first 3 months (2) and then more slowly in the following year. The first day, decreased oedema and partial reperfusion of the ischemic penumbra may possibly explain these phenomena, but the improvement of neurological deficit in the following weeks suggests plasticity phenomena and brain cortical reorganization (3). While most recovery is thought to be made in the first few weeks after stroke, patients may make improvements on functional tasks many months after having a stroke (4). Restoring arm and hand skill after a stroke remains challenging, even though stroke rehabilitation programs have proven partial efficacy Repetitive task training has been shown to be effective in some aspects of rehabilitation, such as improving walking distance and speed and improving upper limb function (5).

In this project, the investigators will use "Gloreha ARIA" (7) a new sensor-based therapy device designed for motor recovery of impaired upper limb Gloreha Aria offers specific programs that help patients to move arm, wrist and fingers. Therapists can customize therapy by focusing on a specific motor task.

Condition or Disease Intervention/Treatment Phase
  • Device: Gloreha Aria
  • Other: Usual care
N/A

Detailed Description

The hypothesis was that rehabilitation with this device could be not inferior in comparison with hands-on physiotherapy, in the reeducation of upper arm in the patient affected by stroke from cerebral ischemia or hemorrhage that had occurred ≤ 30 days before.

The principle purpose of this study will be to evaluate:
  1. The feasibility of this new device

  2. Efficacy in improving arm function abilities in the rehabilitation of patients with stroke in the sub-acute phase.

Post-stroke patients admitted for inpatient rehabilitation to the Neurological Rehabilitation will be screened for enrolment and randomized in a controlled trial.

All the patients will be informed about the aim and experimental procedures before enrolment, thus written informed consent will be obtained from all of them. Patients included in the study will be randomly assigned to intervention or control group according to simple randomization technique (computerized random numbers).

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Feasibility and Efficacy of the Upper Limb Treatment With "Gloreha Aria" in the Hemiplegic Patients: a Randomized Pilot Study
Actual Study Start Date :
Jul 1, 2018
Actual Primary Completion Date :
Jun 30, 2021
Actual Study Completion Date :
Sep 7, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment Group

The specific hand intervention consisted of 30 sessions, lasting 60 min/ day, for 6 days/week. All patients will be educated by physiotherapist to perform the movements for wrist, hand and arm in complete autonomy. In Treatment Group, the movements will be performed using Gloreha ARIA. Gloreha Aria is a sensor-based therapy device designed for motor recovery of impaired upper limb. Gloreha Aria is equipped with sensors that can detect any movements in space: the software processes and displays them on the screen.

Device: Gloreha Aria
Device offers specific programs that help patients to move arm, wrist and fingers

Active Comparator: Participants Usual Care (PUC)

The specific hand intervention consisted of 30 sessions, lasting 60 min/ day, for 6 days/week. All patients will be educated by physiotherapist to perform the movements for wrist, hand and arm in complete autonomy.In Control Group, these activates will be performed without any device.

Other: Usual care
Conventional occupational therapy

Outcome Measures

Primary Outcome Measures

  1. Change from baseline of FMA-UE (Fugl-Meyer assessment upper extremity). [From date of randomization (T0) until the to the end of the study (T1) after an intervention lasting over a period of about 6 weeks, assessed after 30 rehabilitation sessions, lasting 30 min/ day each and performed 5 days/week.]

    Assessment of sensorimotor function.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • to exhibit first cerebral vascular disease with unilateral hemispherical lesion confirmed by CT scan or MRI;

  • to be sub-acute patients (less than 30 days from the cerebral vascular event);

  • being affected by upper limb paresis;

Exclusion Criteria:
  1. unable to understand verbal instruction or motor commands;

  2. unilateral neglect;

  3. apraxia;

  4. significant visual impairment;

  5. unstable medical condition;

  6. significant orthopedic limitation to the shoulder, elbow; wrist and hand;

  7. upper arm peripherical nerve lesion;

  8. neuromuscular or neurodegenerative diseases;

  9. spasticity > 3 in according to the Modifies Ashworth Scale (3);

Contacts and Locations

Locations

Site City State Country Postal Code
1 Istituti Clinici Scientifici Maugeri IRCCS Pavia Italy 27100

Sponsors and Collaborators

  • Istituti Clinici Scientifici Maugeri SpA

Investigators

  • Principal Investigator: Fabio Vanoglio, PT, Istituti Clinici Scientifici Maugeri

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Istituti Clinici Scientifici Maugeri SpA
ClinicalTrials.gov Identifier:
NCT03738813
Other Study ID Numbers:
  • ICS Maugeri - CE 2208
First Posted:
Nov 13, 2018
Last Update Posted:
Sep 8, 2021
Last Verified:
Sep 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 8, 2021